-
Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL_Matthew Davids, MD, MMSc
41:32
-
Updates in Management for Relapsed and Refractory CLL_Nicole Lamanna, MD; #hemeupdates2022
19:49
-
Novel Agents in CLL_John Allan, MD; #hemeupdates2022
14:57
-
New Therapeutic Options in Frontline CLL_Richard Furman, MD; #hemeupdates2022
15:59
-
New therapeutic options in frontline CLL_Susan O'Brien, MD; #BeyondTheCongress
14:51
-
Novel agents in CLL_Nitin Jain, MD; #BeyondTheCongress
14:25
-
Updates in management for relapsed and refractory CLL_Jennifer Brown, MD, PhD; #BeyondTheCongress
14:29
-
Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting_Jennifer Woyach, MD_Matthew Davids, MD, MMSc
31:18
-
Nicole Lamanna, MD; Columbia University Irving Medical Center; 5Live #ASH21
11:27
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Javier Pinilla-Ibarz, MD, PhD; Moffit Cancer Center; 5Live #ASH21
12:43
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Jennifer Woyach, MD; Ohio State; 5Live #ASH21
5:16
Key insights from the 2021 Annual Hematology meeting in Atlanta
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company